After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...
Zacks.com on MSN3h
FATE Presents Encourgaing Data From Lupus Study, Stock GainsFate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...
Live Science on MSN7h
'Like a reset button on a computer': Designer cells 'reboot' immune system in 3 different autoimmune diseasesA small trial used designer CAR T cells to reboot the immune systems of patients with three autoimmune diseases, but it's ...
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...
ZME Science on MSN5d
Could CAR-T Therapy Be the End of Lifelong Lupus Medication? Early Results Say ‘Yes’T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...
"Lupus was the perfect disease for us!" showrunner David Shore says with a laugh ahead of the 20th anniversary.
The new treatment works by genetically modifying a person's cells to fight the disease. It has been used on patients in ...
For those with lupus, Botox has a heightened risk of side effects. It can also interact with your lupus medications, so it's ...
Nuru had a stint as adviser at the World Bank-backed Sustainable Banking & Finance Network, a platform for knowledge sharing ...
The patient achieved clinical remission and low lupus disease activity state as of Month 6 follow-up. The patient continues on-study, in clinical remission, and free of all immunosuppressive therapies ...
Artificial intelligence is making impressive strides in its ability to read medical images. In a recent test in Britain's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback